Trial Profile
Phase 1/2 Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults with Osteosarcoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 13 Jul 2023
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary) ; Etoposide; Ifosfamide
- Indications Osteosarcoma; Solid tumours; Thyroid cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eisai Co Ltd
- 02 Feb 2023 This trial has been completed in Spain, according to European Clinical Trials Database record.
- 03 Aug 2022 Status changed from active, no longer recruiting to completed.
- 08 Jun 2022 Planned End Date changed from 31 Mar 2022 to 11 Jul 2022.